We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Recommendations Forsake Metal-on-Metal Hip Implants

By HospiMedica International staff writers
Posted on 11 Jul 2012
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) is looking for guidance on how to monitor patients who have received metal-on-metal implants.

The FDA has recently revealed that it had received 16,800 negative-event reports involving metal hips between 2000 and 2011. More...
Of those, more than 14,000 involved revision surgeries, in which a defective implant was removed. Following these reports and a growing concern over all-metal hip implants, the FDA convened the 18-member Orthopedic and Rehabilitation Devices Panel of experts over a two-day hearing to examine data from around the world on the metal implants, following reports that the devices break down at higher rates than plastic- or ceramic-coated models, and that the resultant metal flakes in the bloodstream can lead to medical complications.

The panel recommended that metal-on-metal hip implant patients who were suffering symptoms of a failing device undergo regular X-rays and blood tests. Revision surgery was recommended for patients whose implants showed signs of failure. A magnetic resonance imaging (MRI) or computerized tomography (CT) scan should be performed in some cases, and follow-up visits should take place at least every three to six months for patients whose X-rays did not show failure, the panel said. They also recommended that all patients with metal-on-metal hip replacement devices undergo annual X-rays to monitor their implants, regardless of symptoms.

“I do not use metal-on-metal hips, and I can see no reason to do so,” said panel chair William Rohr, MD, of Mendocino Coast District Hospital (Fort Bragg, CA, USA), according to a report in the Associated Press.

The panel also recommended including label warnings about pseudo-tumors and high levels of metal ions in patients’ blood, as well as a recommendation for a warning stating that metal-on-metal hip implant recipients are more sensitive to the devices’ positioning than patients with other types. The panel was not asked to make recommendations whether or not the devices should undergo more extensive testing, or be subjected to additional regulation.

Related Links:

US Food and Drug Administration
Mendocino Coast District Hospital



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.